Risedronate Oral Tablet
( DrugBank: Risedronate / KEGG DRUG: Risedronic acid )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 274 | 骨形成不全症 | 6 |
274. 骨形成不全症
臨床試験数 : 91 / 薬物数 : 101 - (DrugBank : 20) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 48
Showing 1 to 6 of 6 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04152551 (ClinicalTrials.gov) | November 2, 201920191102 | 18/10/201920191018 | Effects of Bisphosphonates on OI-Related Hearing Loss | Effects of Bisphosphonates on OI-Related Hearing Loss: A Pilot Study | Osteogenesis Imperfecta | Drug: Risedronate Oral Tablet | Hospital for Special Surgery, New York | The New York Community Trust;East River Medical Imaging;Northwell Health | Recruiting | 6 Years | 100 Years | All | 100 | Phase 4 | United States |
| 2 | EUCTR2004-000485-13-DK (EUCTR) | 29/01/200720070129 | 29/11/200620061129 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | Osteogenesis Imperfecta MedDRA version: 8.1;Level: LLT;Classification code 10031243;Term: Osteogenesis imperfecta Osteogenesis Imperfecta MedDRA version: 8.1;Level: LLT;Classification code 10031243;Term: Osteogenes ... | Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Trade Name: Optinate 5 mg filmcoated tablets Product Name: Risedronate sodium 5mg INN or Proposed INN: risedronic acid Product Name: risedronatesodium 2.5mg INN or Proposed INN: risedronic acid Trade Name: Optinate 5 mg f ... | Procter & Gamble Ltd | NULL | Not Recruiting | Female: yes Male: yes | 124 | Hungary;Finland;Czech Republic;Denmark;Spain | |||
| 3 | EUCTR2004-000485-13-CZ (EUCTR) | 04/10/200620061004 | 25/08/200620060825 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | Osteogenesis Imperfecta | Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronate sodium 5mg INN or Proposed INN: risedronic acid Product Name: risedronatesodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronateso ... | Procter & Gamble Ltd | NULL | Not Recruiting | Female: yes Male: yes | 124 | Phase 3 | Hungary;Czech Republic;Finland;Spain;Belgium;Denmark | ||
| 4 | EUCTR2004-000485-13-HU (EUCTR) | 25/08/200620060825 | 14/07/200620060714 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | Osteogenesis Imperfecta | Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronate sodium 5mg INN or Proposed INN: risedronic acid Product Name: risedronatesodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronateso ... | Procter & Gamble Ltd | NULL | Not Recruiting | Female: yes Male: yes | 124 | Finland;Hungary;Czech Republic;Denmark;Spain | |||
| 5 | EUCTR2004-000485-13-BE (EUCTR) | 22/08/200620060822 | 30/05/200620060530 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | Osteogenesis Imperfecta | Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronate sodium 5mg INN or Proposed INN: risedronic acid Product Name: risedronatesodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronateso ... | Procter & Gamble Ltd | NULL | Not Recruiting | Female: yes Male: yes | 124 | Czech Republic;Hungary;Finland;Spain;Belgium;Denmark | |||
| 6 | EUCTR2004-000485-13-FI (EUCTR) | 28/03/200620060328 | 10/02/200620060210 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | Osteogenesis Imperfecta | Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Trade Name: Actonel/Optinate 5mg film-coated tablets Product Name: Risedronate sodium 5mg INN or Proposed INN: risedronic acid Product Name: risedronatesodium 2.5mg INN or Proposed INN: risedronic acid Trade Name: Actonel/Optinat ... | Procter & Gamble Ltd | NULL | Not Recruiting | Female: yes Male: yes | 124 | Hungary;Finland;Czech Republic;Denmark;Spain |